<DOC>
	<DOCNO>NCT00491803</DOCNO>
	<brief_summary>Sildenafil phosphodiesterase-5 inhibitor approve treatment pulmonary arterial hypertension orphan drug designation . Sildenafil modulate nitric oxide ( NO ) pathway vessel wall . Since pathway impaired pulmonary artery patient pulmonary hypertension ( PH ) associate chronic obstructive pulmonary disease ( COPD ) , hypothesize sildenafil might improve pulmonary hemodynamics increase exercise tolerance condition . However , COPD sildenafil may also impair gas exchange due inhibition pulmonary hypoxic vasoconstriction . The research project aim evaluate effect . It prospective , randomize , double-blind study evaluate acute effect single dose 20 40 mg sildenafil gas exchange pulmonary hemodynamics . Subjects : 20 patient ( 10 group ) . Measurements : pulmonary hemodynamics , arterial blood gas ventilation-perfusion distribution ; rest sub-maximal exercise .</brief_summary>
	<brief_title>Sildenafil Effects Pulmonary Haemodynamics Gas Exchange Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>COPD ( FEV1/FVC &lt; 0.7 ) Age 4075 Pulmonary hypertension ( Vmax TI &gt; =2.8m/sec ) Treatment CYP3A4 inhibitor , nitrate , PDE5 inhibitor Coronary disease Ischemic optical neuritis</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>COPD</keyword>
</DOC>